PCSK9 inhibitors and their role in high-risk patients in reducing LDL cholesterol levels: evolocumab

被引：4

作者：

Dahagam, Chanukya ^{[1
]}

Goud, Aditya ^{[1
]}

Abdelqader, Abdelhai ^{[1
]}

Hendrani, Aditya ^{[2
]}

Feinstein, Matthew J. ^{[3
]}

Qamar, Arman ^{[4
]}

Joshi, Parag H. ^{[5
]}

Swiger, Kristopher J. ^{[6
]}

Byrne, Kathleen ^{[7
]}

Quispe, Renato ^{[8
]}

Jones, Steven R. ^{[8
]}

Blumenthal, Roger S. ^{[8
]}

Martin, Seth S. ^{[8
]}

机构：

[1] MedStar Franklin Sq Med Ctr, Dept Med, Baltimore, MD USA

[2] MedStar Good Samaritan Union Mem Hosp, Dept Med, Baltimore, MD USA

[3] Northwestern Univ, Dept Prevent Med, Feinberg Sch Med, Chicago, IL 60611 USA

[4] Brigham & Womens Hosp, Div Cardiovasc, 75 Francis St, Boston, MA 02115 USA

[5] Univ Texas Southwestern Med Ctr Dallas, Div Cardiovasc, Dallas, TX 75390 USA

[6] Vanderbilt Univ, Div Cardiovasc, Med Ctr, Nashville, TN USA

[7] Johns Hopkins Univ Hosp, Pediat Cardiol, Baltimore, MD 21287 USA

[8] Johns Hopkins Univ, Sch Med, Johns Hopkins Ciccarone Ctr Prevent Heart Dis, Div Cardiol,Dept Med, 600 North Wolfe St,Carnegie 591, Baltimore, MD 21287 USA

来源：

FUTURE CARDIOLOGY | 2016年 / 12卷 / 02期

关键词：

alirocumab; evolocumab; LDL; monoclonal antibodies; PCSK9; inhibitors; statin intolerance;

D O I：

10.2217/fca.15.89

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Patients with familial hypercholesterolemia or statin intolerance are especially challenging to manage since LDL cholesterol levels often remain considerably elevated despite clinicians' best efforts. With statins regarded as first-line pharmacologic therapy by the current American College of Cardiology/American Heart Association guidelines to reduce LDL cholesterol and cardiovascular risk, there is now a critical need to determine when other agents will play a role beyond maximally tolerated statin therapy and lifestyle changes. In this review, we take a closer look at evolocumab (Repatha (R)), one of the new injectable human monoclonal antibodies to PCSK9 and its efficacy and safety properties from the results of various trials.

引用

页码：139 / 148

页数：10

共 59 条

[1] Mutations in PCSK9 cause autosomal dominant hypercholesterolemia [J].

Abifadel, M ;

Varret, M ;

Rabès, JP ;

Allard, D ;

Ouguerram, K ;

Devillers, M ;

Cruaud, C ;

Benjannet, S ;

Wickham, L ;

Erlich, D ;

Derré, A ;

Villéger, L ;

Farnier, M ;

Beucler, I ;

Bruckert, E ;

Chambaz, J ;

Chanu, B ;

Lecerf, JM ;

Luc, G ;

Moulin, P ;

Weissenbach, J ;

Prat, A ;

Krempf, M ;

Junien, C ;

Seidah, NG ;

Boileau, C .

NATURE GENETICS, 2003, 34 (02) :154-156

[2]

[Anonymous], 2015, REP EV PRESCR INF

[3] Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins [J].

Baigent, C ;

Keech, A ;

Kearney, PM ;

Blackwell, L ;

Buck, G ;

Pollicino, C ;

Kirby, A ;

Sourjina, T ;

Peto, R ;

Collins, R ;

Simes, J .

LANCET, 2005, 366 (9493) :1267-1278

[4] Statin intolerance - an attempt at a unified definition. Position paper from an International Lipid Expert Panel [J].

Banach, Maciej ;

Rizzo, Manfredi ;

Toth, Peter P. ;

Farnier, Michel ;

Davidson, Michael H. ;

Al-Rasadi, Khalid ;

Aronow, Wilbert S. ;

Athyros, Vasilis ;

Djuric, Dragan M. ;

Ezhov, Marat V. ;

Greenfield, Robert S. ;

Hovingh, G. Kees ;

Kostner, Karam ;

Serban, Corina ;

Lighezan, Daniel ;

Fras, Zlatko ;

Moriarty, Patrick M. ;

Muntner, Paul ;

Goudev, Assen ;

Ceska, Richard ;

Nicholls, Stephen J. ;

Broncel, Marlena ;

Nikolic, Dragana ;

Pella, Daniel ;

Puri, Raman ;

Rysz, Jacek ;

Wong, Nathan D. ;

Bajnok, Laszlo ;

Jones, Steven R. ;

Ray, Kausik K. ;

Mikhailidis, Dimitri P. .

ARCHIVES OF MEDICAL SCIENCE, 2015, 11 (01) :1-23

[5]

Baris G, 2015, SWISS MED WEEKLY, V145

[6] A 52-Week Placebo-Controlled Trial of Evolocumab in Hyperlipidemia [J].

Blom, Dirk J. ;

Hala, Tomas ;

Bolognese, Michael ;

Lillestol, Michael J. ;

Toth, Phillip D. ;

Burgess, Lesley ;

Ceska, Richard ;

Roth, Eli ;

Koren, Michael J. ;

Ballantyne, Christie M. ;

Monsalvo, Maria Laura ;

Tsirtsonis, Kate ;

Kim, Jae B. ;

Scott, Rob ;

Wasserman, Scott M. ;

Stein, Evan A. .

NEW ENGLAND JOURNAL OF MEDICINE, 2014, 370 (19) :1809-1819

[7] Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes [J].

Cannon, Christopher P. ;

Blazing, Michael A. ;

Giugliano, Robert P. ;

McCagg, Amy ;

White, Jennifer A. ;

Theroux, Pierre ;

Darius, Harald ;

Lewis, Basil S. ;

Ophuis, Ton Oude ;

Jukema, J. Wouter ;

De Ferrari, Gaetano M. ;

Ruzyllo, Witold ;

De Lucca, Paul ;

Im, KyungAh ;

Bohula, Erin A. ;

Reist, Craig ;

Wiviott, Stephen D. ;

Tershakovec, Andrew M. ;

Musliner, Thomas A. ;

Braunwald, Eugene ;

Califf, Robert M. .

NEW ENGLAND JOURNAL OF MEDICINE, 2015, 372 (25) :2387-2397

[8] A proprotein convertase subtilisin/kexin type 9 neutralizing antibody reduces serum cholesterol in mice and nonhuman primates [J].

Chan, Joyce C. Y. ;

Piper, Derek E. ;

Cao, Qiong ;

Liu, Dongming ;

King, Chadwick ;

Wang, Wei ;

Tang, Jie ;

Liu, Qiang ;

Higbee, Jared ;

Xia, Zhen ;

Di, Yongmei ;

Shetterly, Susan ;

Arimura, Ziva ;

Salomonis, Heather ;

Romanow, William G. ;

Thibault, Stephen T. ;

Zhang, Richard ;

Cao, Ping ;

Yang, Xiao-Ping ;

Yu, Timothy ;

Lu, Mei ;

Retter, Marc W. ;

Kwon, Gayle ;

Henne, Kirk ;

Pan, Oscar ;

Tsai, Mei-Mei ;

Fuchslocher, Bryna ;

Yang, Evelyn ;

Zhou, Lei ;

Lee, Ki Jeong ;

Daris, Mark ;

Sheng, Jackie ;

Wang, Yan ;

Shen, Wenyan D. ;

Yeh, Wen-Chen ;

Emery, Maurice ;

Walker, Nigel P. C. ;

Shan, Bei ;

Schwarz, Margrit ;

Jackson, Simon M. .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2009, 106 (24) :9820-9825

[9] Design and Rationale of the GAUSS-2 Study Trial: A Double-Blind, Ezetimibe-Controlled Phase 3 Study of the Efficacy and Tolerability of Evolocumab ( AMG145) in Subjects With Hypercholesterolemia Who Are Intolerant of Statin Therapy [J].

Cho, Leslie ;

Rocco, Michael ;

Colquhoun, David ;

Sullivan, David ;

Rosenson, Robert S. ;

Dent, Ricardo ;

Xue, Allen ;

Scott, Rob ;

Wasserman, Scott M. ;

Stroes, Erik .

CLINICAL CARDIOLOGY, 2014, 37 (03) :131-139

[10] Profile of evolocumab and its potential in the treatment of hyperlipidemia [J].

Cicero, Arrigo F. G. ;

Colletti, Alessandro ;

Borghi, Claudio .

DRUG DESIGN DEVELOPMENT AND THERAPY, 2015, 9 :3073-3082

← 1 2 3 4 5 6 →